Tabelecleucel for EBV-related lymphoma after transplant treatment failure
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a solid organ transplant (kidney, liver, heart, lungs, pancreas, small bowel) or an allogeneic bone marrow/stem cell transplant
- Your biopsy-confirmed PTLD is linked to EBV (EBV positive)
- Your scans show measurable body disease that lights up on PET (Deauville score 3 or higher), unless a scan type is required by your clinic
- Your PTLD did not respond or has progressed after rituximab (or a similar biosimilar) and/or rituximab plus chemotherapy
- Your blood counts and organs are strong enough for treatment (specific minimum levels for white cells, platelets, liver tests)
- You can give consent and meet age/activity needs (good enough daily functioning for your age)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests whether a drug called rituximab can prevent a type of cancer called PTLD in people who have had an organ transplant and are showing signs of an EBV infection. EBV is a common virus that can be more dangerous for transplant patients, and this study aims to see if using rituximab early can stop PTLD from developing.
Hear when a new Solid Organ Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.